Table 1.
Patient demographics
| Variable | Mean ± SD (range) | Number | % |
|---|---|---|---|
| Age, yr | 49.0 ± 9.3 (24-77) | ||
| ≤ 50 | 680 | 63.8 | |
| > 50 | 385 | 36.2 | |
| Duration of ET, yr | 5.0 ± 1.0 (0.9-7.9) | ||
| ET regimen | |||
| Tamoxifen 5 yr | 657 | 61.7 | |
| Tamoxifen 2-3 yr - > AI (total 5 yr) yr | 41 | 3.8 | |
| Tamoxifen 5 yr - > AI | 192 | 18 | |
| AI 5 yr | 16.4 | ||
| Tumor size (cm) | 2.1 ± 1.4 (0.1-10.0) | ||
| ≤ 2 cm | 638 | 59.9 | |
| > 2 cm | 427 | 40.1 | |
| Lymph node status | |||
| Negative | 706 | 66.3 | |
| Positive | 359 | 33.7 | |
| Histologic grade | |||
| Low/Intermediate | 825 | 77.5 | |
| High | 240 | 22.5 | |
| Progesterone receptor | |||
| Negative | 477 | 44.8 | |
| Positive | 588 | 55.2 | |
| HER2 | |||
| Negative | 976 | 91.6 | |
| Positive | 88 | 8.3 | |
| Ki-67 | |||
| < 10 | 895 | 84 | |
| ≥ 10 | 169 | 15.9 | |
| Neoadjuvant chemotherapy | |||
| No | 1017 | 95.5 | |
| Yes | 48 | 4.5 | |
| Operation | |||
| Breast conserving surgery | 667 | 62.6 | |
| Mastectomy | 398 | 37.4 | |
| Adjuvant chemotherapy | |||
| No | 247 | 23.2 | |
| Yes | 818 | 76.8 | |
| Radiotherapy | |||
| No | 408 | 38.3 | |
| Yes | 657 | 61.7 | |
| Recurrence | |||
| Total | 80 | 7.5 | |
| Locoregional | 21 | 26.2 | |
| Contralateral breast | 8 | 10 | |
| Distant metastasis | 51 | 63.8 |
Clinicopathological factors of the 1065 patients. ET: endocrine therapy; AI: aromatase inhibitor; HER2: Human Epidermal Growth Factor Receptor 2.